Corbus Pharmaceuticals Holding
$ 10.59
4.44%
17 Apr - close price
- Market Cap 187,829,000 USD
- Current Price $ 10.59
- High / Low $ 11.00 / 10.15
- Stock P/E N/A
- Book Value 8.38
- EPS -5.90
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.54 %
- 52 Week High 20.56
- 52 Week Low 5.90
About
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
Analyst Target Price
$40.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-09 | 2025-11-12 | 2025-08-05 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -1.25 | -1.9 | -1.44 | -1.3914 | -0.78 | -1.15 | -0.9 | -0.83 | -1.81 | -2.05 | -2.05 | -4.24 |
| Estimated EPS | -1.576 | -1.28 | -1.23 | -1.0729 | -1.2589 | -0.95 | -1.19 | -1.09 | -2.36 | -2.06 | -3.1 | -4.09 |
| Surprise | 0.326 | -0.62 | -0.21 | -0.3185 | 0.4789 | -0.2 | 0.29 | 0.26 | 0.55 | 0.01 | 1.05 | -0.15 |
| Surprise Percentage | 20.6853% | -48.4375% | -17.0732% | -29.6859% | 38.0411% | -21.0526% | 24.3697% | 23.8532% | 23.3051% | 0.4854% | 33.871% | -3.6675% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRBP
2026-04-17 17:19:00
Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price increase by 4.44% to $10.59 on Friday, outperforming the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average also experienced significant gains, with CRBP marking its second consecutive day of increases.
2026-04-17 15:09:52
Corbus Pharmaceuticals has updated the employment agreements for its CEO, Yuval Cohen, Ph.D., and CFO, Sean Moran, effective April 15, 2026. Both executives have two-year terms, with Dr. Cohen's annual base salary set at $673,625 and Mr. Moran's at $501,273, along with eligibility for performance-based bonuses and equity awards. These updates come as the company navigates a challenging stock performance but also recent progress in its clinical trials and positive analyst ratings.
2026-04-17 14:05:21
Mizuho has reiterated an Outperform rating and raised its price target for Corbus Pharmaceuticals Holdings, Inc. (CRBP) from $39 to $40, citing an attractive risk-reward profile, especially with the stock trading near its cash value. The company anticipates three clinical data readouts in 2026, which are seen as significant catalysts. Additionally, Corbus has aligned with the U.S. FDA on a registration strategy for CRB-701, a drug for head and neck squamous cell carcinoma and cervical cancer, involving separate randomized controlled studies.
2026-04-17 02:40:21
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has updated the employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026. The new two-year agreements outline their base salaries, bonus eligibility, equity awards, and severance terms, amid a challenging period for the company, although its stock has seen a strong annual return. These updates coincide with other positive developments, including the completion of enrollment for a Phase 1b clinical trial and reiterated "buy" ratings from Jefferies and Mizuho.
2026-04-17 02:39:18
Corbus Pharmaceuticals recently updated the employment agreements for CEO Yuval Cohen and CFO Sean Moran, extending their terms until April 2028. These amendments enhance severance, equity, and change-of-control protections, aiming to ensure leadership stability and align executive interests with shareholders. While the company faces financial challenges, a recent analyst rating suggests a Buy for CRBP stock, with Spark's AI Analyst giving a Neutral score.
2026-04-16 20:39:18
Corbus Pharmaceuticals (NASDAQ: CRBP) has updated the employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026, through April 15, 2028. The new terms outline base salaries, target bonuses, and enhanced severance and equity vesting protections, especially during a change in control period. Both executives are also subject to non-compete and non-solicitation clauses.
